Margetuximab Plus Chemo Reveals Intriguing Benefit in HER2+ Breast Cancer

Ellie Leick
Published: Tuesday, Jan 14, 2020
Hope Rugo, MD, a professor in the Department of Medicine and director of Breast Oncology and Clinical Trials Education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center

Hope Rugo, MD

Updated findings of the phase III SOPHIA trial showed that margetuximab plus chemotherapy led to an increase in progression-free survival (PFS) and an overall survival (OS) compared with trastuzumab (Herceptin) plus chemotherapy in patients with HER2-positive metastatic breast cancer who had previously received HER2-targeted therapies, explained Hope S. Rugo, MD, FASCO.

The second interim OS analysis was based off of 270 OS events and showed that, at a median follow-up of 15.6 months, the median OS in the intent-to-treat population was 21.6 months (95% CI, 18.86-24.05) with margetuximab plus chemotherapy versus 19.8 months (95% CI, 17.54-22.28) with trastuzumab plus chemotherapy (HR, 0.89; 95% CI, 0.69-1.13; P = .326). The final prespecified OS analysis is planned after 385 events have occurred, which will likely occur in late 2020.

The investigator-assessed PFS showed a 29% reduction in the risk of disease progression or death with margetuximab compared with the trastuzumab arm. The median PFS for margetuximab/chemotherapy was 5.7 months (95% CI, 5.22-6.97) versus 4.4 months (95% CI, 4.14-5.45) for trastuzumab/chemotherapy (HR, 0.71; 95% CI, 0.58-0.86; P = .0006).

“Overall, the SOPHIA trial showed that margetuximab is safe and similar to trastuzumab and can be given [to patients with HER2-positive breast cancer],” said Rugo, a professor in the Department of Medicine and director of Breast Oncology and Clinical Trials Education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x